Accelerated partial breast irradiation using the strut-adjusted volume implant single-entry hybrid catheter in brachytherapy for breast cancer in the setting of breast augmentation

被引:21
作者
Bloom, Elizabeth S. [1 ]
Kirsner, Steve [2 ]
Mason, Bryan E. [2 ]
Nelson, Chris L. [2 ]
Hunt, Kelly K. [3 ]
Baumann, Donald P. [4 ]
Gifford, Kent A. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Radiat Treatment Ctr Bellaire, Div Radiat Oncol, Houston, TX 77081 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Radiat Phys, Houston, TX 77081 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77081 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Houston, TX 77081 USA
关键词
Accelerated partial breast irradiation; Breast augmentation; Brachytherapy; SAVI; CONSERVING THERAPY; RADIATION-THERAPY; DEVICE;
D O I
10.1016/j.brachy.2010.06.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: Accelerated partial breast irradiation (APBI) has gained popularity as an alternative to adjuvant whole breast irradiation; however, owing to limitations of delivery devices for brachytherapy, APBI has not been a suitable option for all the patients. This report evaluates APBI using the strut-adjusted volume implant (SAVI) single-entry catheter to deliver brachytherapy for breast cancer in the setting of an augmented breast. METHODS AND MATERIALS: The patient previously had placed bilateral subpectoral saline implants; stereotactic core biopsy revealed estrogen receptor- and progesterone receptor-positive ductal carcinoma in situ of intermediate nuclear grade. The patient underwent needle-localized segmental mastectomy of her left breast; pathologic specimen revealed no residual malignancy. An SAVI 8-1 device was placed within the segmental resection cavity. Treatment consisted of 3.4 Gy delivered twice a day for 5 days for a total dose of 34 Gy. Treatments were delivered with a high-dose-rate (192)Ir remote afterloader. RESULTS: Conformance of the device to the lumpectomy cavity was excellent at 99.2%. Dosimetric values of percentage of the planning target volume for evaluation receiving 90% of the prescribed dose, percentage of the planning target volume for evaluation receiving 95% of the prescribed dose, volume receiving 150% of the prescribed dose, and volume receiving 200% of the prescribed dose were 97.1%, 94.6%, 22.7 cc, and 11.6 cc, respectively. Maximum skin dose was 115% of the prescribed dose. The patient tolerated treatment well with excellent cosmetic results, and limited acute and late toxicity at 8 weeks and 6 months, respectively. CONCLUSIONS: Breast augmentation should not be an exclusion criterion for the option of APBI. The SAVI single-entry catheter is another option to successfully complete APBI using brachytherapy for breast cancer in the setting of an augmented breast. (C) 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:178 / 183
页数:6
相关论文
共 15 条
  • [1] [Anonymous], NSABP PROTOCOL B 39
  • [2] A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: Tumor control and survival outcomes of RTOG 95-17
    Arthur, Douglas W.
    Winter, Kathryn
    Kuske, Robert R.
    Bolton, John
    Rabinovitch, Rachel
    White, Julia
    Hanson, William F.
    Wilenzick, Raymond M.
    McCormick, Beryl
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02): : 467 - 473
  • [3] Partial breast irradiation in breast-conserving therapy by way of interstitial brachytherapy
    Benitez, PR
    Chen, PY
    Vicini, FA
    Wallace, M
    Kestin, L
    Edmundson, G
    Gustafson, G
    Martinez, A
    [J]. AMERICAN JOURNAL OF SURGERY, 2004, 188 (04) : 355 - 364
  • [4] Skin and chest wall dose with multi-catheter and MammoSite breast brachytherapy: Implications for late toxicity
    Cuttino, Laurie W.
    Todor, Dorin
    Rosu, Miheala
    Arthur, Douglas W.
    [J]. BRACHYTHERAPY, 2009, 8 (02) : 223 - 226
  • [5] Technology Insight:: MammoSite® -: a new device for delivering brachytherapy following breast-conserving therapy
    Dickler, Adam
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (03): : 190 - 196
  • [6] Dickler Adam, 2005, Brachytherapy, V4, P130, DOI 10.1016/j.brachy.2004.12.003
  • [7] ANALYSIS OF COSMETIC RESULTS FOLLOWING PRIMARY RADIATION-THERAPY FOR STAGE-1 AND STAGE-2 CARCINOMA OF THE BREAST
    HARRIS, JR
    LEVENE, MB
    SVENSSON, G
    HELLMAN, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1979, 5 (02): : 257 - 261
  • [8] Long-term results of wide field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis,1,2 breast cancer
    King, TA
    Bolton, JS
    Kuske, RR
    Fuhrman, GM
    Scroggins, TG
    Jiang, XZ
    [J]. AMERICAN JOURNAL OF SURGERY, 2000, 180 (04) : 299 - 304
  • [9] Augmentation mammoplasty: effect on diagnosis of breast cancer
    McIntosh, S. A.
    Horgan, K.
    [J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2008, 61 (02) : 124 - 129
  • [10] Partial-breast treatment for early breast cancer: emergence of a new paradigm
    Sarin, R
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (01): : 40 - 47